CA125: An Increasingly Promising Biomarker of Heart Failure

Author(s): Chunqi Pan, Mengyun Zhou, Ying Jian, Yuanyuan Zeng, Mingwei Wang*, Feng Chen*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 37 , 2021

Become EABM
Become Reviewer
Call for Editor


CA125 is a well-known tumor marker for diagnosis, monitoring, and risk stratification in ovarian cancer. It is not specific for malignant tumors and may be elevated in benign disease. In the past two decades, increasing evidence has emerged suggesting that the plasma level of CA125 can serve as a novel surrogate of heart failure (HF). CA125 in patients with HF is synthesized by serous epithelial cells in response to both mechanical and inflammatory stimuli. In patients with HF, regardless of etiology, CA125 levels correlate with the severity of clinical, hemodynamic, and echocardiographic parameters and with other biomarkers. Elevated CA125 can identify patients at high risk of rehospitalization and mortality, whether short- or long-term. Serial measurements and combination with different pathophysiology biomarkers can provide a more accurate prognosis value. It also can guide treatment as a robust biomarker of fluid overload and inflammation, particularly for diuretic dose optimization. These properties make it a very promising candidate for risk stratification and treatment guidance of HF.

Keywords: CA125, biomarker, heart failure, echocardiographic and hemodynamics parameters, risk stratification, cytokines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 18 January, 2021
Page: [3871 - 3880]
Pages: 10
DOI: 10.2174/1381612827666210118122521
Price: $65

Article Metrics

PDF: 223